Supplementary file 1_The predictive value of glycated CD59 for fetal overgrowth in second-trimester pregnant women.docx

The pregnant women were followed up until after delivery, and data on delivery-related information and pregnancy outcomes were collected. Differences in pregnancy outcomes between the two groups were compared. Logistic regression analysis was used to identify risk factors for adverse pregnancy outcomes, and the predictive value of gCD59 levels for adverse pregnancy outcomes was assessed using ROC curves.</p>Results<p>Macrosomia and Large for Gestational Age (LGA) were the two most common adverse pregnancy outcomes.

Compared with the NGT group, the incidence of macrosomia and LGA was significantly higher in the GDM group (P < 0.05). Compared with the NGT group, gCD59 levels were significantly higher in the GDM group (1.49 (0.90, 2.33) vs. 0.87 (0.39, 1.62), P < 0.001). Logistic regression analysis indicated that gCD59 was an independent risk factor for macrosomia and LGA, and the incidence of macrosomia and LGA increased with rising gCD59 levels.

In predictive modeling, the addition of gCD59 to traditional risk factors improved the AUC for macrosomia from 0.770 (95% CI: 0.679–0.833) to 0.864 (95% CI: 0.823–0.904) (DeLong P = 0.046); for LGA, the AUC improved from 0.723 (95% CI: 0.663–0.782) to 0.790 (95% CI: 0.737–0.843) (DeLong P = 0.103).</p>Conclusion<p>Macrosomia and LGA were the most common adverse pregnancy outcomes in the study cohort. gCD59 was identified as an independent risk factor for both macrosomia and LGA.

In predictive modeling, gCD59 demonstrated statistically significant incremental value for macrosomia (AUC: 0.770 vs. 0.864, DeLong P = 0.046), while for LGA the improvement showed a favorable trend but did not reach statistical significance (AUC: 0.723 vs. 0.790, DeLong P = 0.103). These findings suggest that gCD59 may serve as a supplementary biomarker, particularly for risk stratification of macrosomia, with potential utility for identifying pregnancies at risk of excessive fetal growth.</p>